Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM study of seladelpar in primary biliary cholangitis with compensated cirrhosis
CTR20253298Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Started Dec 2025; status: active.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20253298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253298.